Vericel

Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024

Retrieved on: 
Thursday, February 15, 2024
Sports medicine, Software, Webcast, Vericel, Telephone

CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024.
  • Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
  • The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations .
  • Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.

Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

Retrieved on: 
Wednesday, November 8, 2023
Growth, Eastern Time Zone, Bromelain, EBITDA, Telephone, Research, Marketing, Webcast, Chondrocyte, Total, Investment, MACI, Sports medicine, Video game, Pharmaceutical industry, Security (finance), Tourism, Cryptocurrency, Bromelain (pharmacology), Vericel

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Gross profit for the quarter ended September 30, 2023 was $30.6 million, or 67% of net revenue, compared to $25.2 million, or 65% of net revenue, for the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $35.7 million, compared to $32.0 million for the same period in 2022.
  • Non-GAAP adjusted EBITDA for the quarter ended September 30, 2023 was $5.4 million, or 12% of net revenue, compared to $3.3 million, or 9% of net revenue, for the third quarter of 2022.
  • As of September 30, 2023, the Company had approximately $149 million in cash, restricted cash and investments, and no debt.

Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023

Retrieved on: 
Wednesday, October 25, 2023
Telephone, Webcast, Vericel, Sports medicine, Software, Online shopping

CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023.
  • Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
  • The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations .
  • Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.

Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

Retrieved on: 
Wednesday, September 20, 2023
Surgeon, Eschar, Bromelain (pharmacology), Burn, Inflammation, TBSA, Sepsis, Patient, Total body surface area, Bromelain, Burns, Sports medicine, Trauma, Body surface area, Dentistry, Vericel

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the U.S. commercial availability of NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns.

Key Points: 
  • Eschar removal is a critical first step in the treatment of burns as it can reduce inflammation, stop burn progression, as well as mitigate infections and sepsis.
  • Surgical excision, which is the current standard of care for eschar removal, often results in the removal of viable tissue.
  • “We are very pleased to announce the U.S. commercial availability of NexoBrid, as it significantly expands our Burn Care franchise and represents an important paradigm shift in the treatment of severe thermal burns,” said Nick Colangelo, President and CEO of Vericel.
  • A first application of NexoBrid may be applied to an area of up to 15% body surface area.

Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

Retrieved on: 
Wednesday, September 6, 2023
Yale University, Science, Orchestra, University, ASTM, Lehman Brothers, Health care, Research, PARS, Mergers and acquisitions, Patient, Physician, Physics, FDA, Vericel, Investment, Management, Motus, Biotronik, Neurophysiology

FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company’s Board of Directors (the “Board”).

Key Points: 
  • FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company’s Board of Directors (the “Board”).
  • “We are excited to have Scott join our Board.
  • During this time, he established strong industry knowledge across the life sciences industry, including substantial therapeutic clinical development and global commercialization experience.
  • Prior to joining Vericel, Mr. Durbin was Chief Financial Officer, Chief Operating Officer and Secretary of Board at Prescient Medical.

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, August 15, 2023
GMP, Data management, Operating cost, Chairperson, Table, VLU, Event, Conference call, Bank statement, Eastern Time Zone, Bromelain (pharmacology), Tax, European Directive on Traditional Herbal Medicinal Products, BCC Lions F.C., Strata Skin Sciences, Research, HERE, Trial of the century, Forecasting, EMA, Committee, European Medicines Agency, Taro Pharmaceuticals, EBITDA, Patient, Sun Pharma, NEXT, Depreciation, Mouth ulcer, Growth, Committee for Medicinal Products for Human Use, Phase, FDA, Carcinoma, Regulation of tobacco by the U.S. Food and Drug Administration, BARDA, BCC, Adjustment, Food, Conference, CHMP, Pharmaceutical industry, Rare-earth element, Medical device, Video game, Bookkeeping, Insurance, Vericel

YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Points: 
  • Second Quarter 2023 Highlights and Recent Developments:
    Shipped NexoBrid finished product to Vericel for the U.S. commercial launch in June 2023.
  • Revenues: Revenues for the second quarter 2023 were $4.8 million, compared to $4.7 million in the second quarter of 2022.
  • Research and development expenses in the second quarter 2023 were $2.0 million compared to $2.2 million in the second quarter of 2022.
  • Operating Results: Operating loss in the second quarter of 2023 was $4.0 million, compared to a $3.7 million loss in the second quarter of 2022.

Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

Retrieved on: 
Wednesday, August 2, 2023
Acceleration, Q3, Marketing, Eastern Time Zone, Telephone, Research, EBITDA, Chondrocyte, Investment, Growth, Bromelain, Webcast, Sports medicine, MACI, Video game, Pharmaceutical industry, Security (finance), Online shopping, Bromelain (pharmacology), Vericel

Record Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year

Key Points: 
  • Record Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year
    CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2023, and provided updated full-year 2023 financial guidance.
  • Gross profit for the quarter ended June 30, 2023 was $29.9 million, or 65% of net revenue, compared to $22.9 million, or 62% of net revenue, for the second quarter of 2022.
  • Net loss for the quarter ended June 30, 2023 was $5.0 million, or $0.11 per diluted share, compared to $9.0 million, or $0.19 per diluted share, for the second quarter of 2022.
  • Non-GAAP adjusted EBITDA for the quarter ended June 30, 2023 was $4.4 million, or 10% of net revenue, compared to $2.8 million, or 7% of net revenue, for the second quarter of 2022.

Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023

Retrieved on: 
Thursday, July 20, 2023
Telephone, Webcast, Vericel, Sports medicine, Software

CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023.

Key Points: 
  • CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023.
  • Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
  • The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations .
  • Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.

MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update

Retrieved on: 
Tuesday, May 30, 2023
Operating cost, Biomedical Advanced Research and Development Authority, Table, VLU, Event, European Operations Management Association, Conference call, Bank statement, Eastern Time Zone, Bromelain (pharmacology), European Medicines Agency, Tax, Deep Insight, HERE, Forecasting, EMA, Development, Incidence, EBITDA, Patient, Investment, NEXT, Depreciation, Mouth ulcer, Growth, Research, Phase, FDA, Adjustment, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, Conference, Food, Safety, Corporate development, Pharmaceutical industry, Management, Renewable energy, Video game, Bookkeeping, Vericel

YAVNE, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Importantly, MediWound is now in a strong financial position, with over $57 million in cash.
  • This provides the company with ample resources to effectively execute its corporate initiatives and drive continuous innovation," stated Ofer Gonen, Chief Executive Officer of MediWound.
  • First Quarter 2023 Highlights and Recent Developments:
    The Company’s global Phase III clinical study for EscharEx is expected to begin in the fourth quarter of 2023.
  • The Company utilized $1.8 million to fund its operating activities in the first quarter of 2023.

Global $70 Billion Regenerative Medicine Market Analysis to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 16, 2023
Health, Pharmaceutical, GSK, Amgen, The Global Institute for Tomorrow, COVID-19, Bayer, Medicine, Infection, Food, Takeda Pharmaceutical Company, Cancer, Foreign Affairs, Paratriathlon, Multinational corporation, DSM-IV codes, Prostate, United States Department of Health and Human Services, AstraZeneca, Lung, Stomach, Colon, Regenerative medicine, Ministry, Death, GSK plc, Criticism of the Food and Drug Administration, Rectum, Patent, Patient, Immune system, Voretigene neparvovec, Conditional sentence, Growth, Integra LifeSciences, Region, FDA, Vericel, B cell, Ministry of Economics (Latvia), United Arab Emirates, Skin, World Health Organization, Novartis, Pharmaceutical industry, Vaccine, Video game, Economics, Research

The "Global Regenerative Medicine Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Material, Application, and Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Regenerative Medicine Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Material, Application, and Region" report has been added to ResearchAndMarkets.com's offering.
  • The Global Regenerative Medicine Market - which grew from approximately US$ 15 billion in 2017 to approximately US$ 30 billion in 2022 - is forecasted to grow further into approximately US$ 70 billion opportunities by 2028, owing to the growing severe diseases, infections, and cancers.
  • Regenerative medicine market is driven by surging trauma cases, genetic disorders, chronic diseases, and other infectious viruses.
  • The rising number of cancer patients worldwide is driving the growth of the regenerative medicine market.